Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ephedra seizure

This article was originally published in The Tan Sheet

Executive Summary

U.S. Marshals seized 200 cases of finished ephedra product, 200 boxes of bulk tablets and nine 25 kilo drums of ephedrine alkaloid raw material thus far in enforcement action against Hi-Tech Pharmaceuticals, FDA announces Feb. 24. The products are labeled as containing 25 mg of ephedrine alkaloids per tablet and are marketed under the names Stimerex-ES, Lipodrene and Betadrene, the agency states. The U.S. Attorney's Office for the Northern District of Georgia also has filed a complaint for forfeiture against the firm; the product is being seized from Hi-Tech's Norcross, Ga. facility. The enforcement action will prevent approximately $3 mil. worth of ephedra products marketed by the company from reaching consumers, FDA adds. High-Tech also faced seizure of its ephedra products by FDA in January (1"The Tan Sheet" Jan. 16, 2005, p. 10). The firm filed a September lawsuit seeking to prevent the agency from enforcing its 2004 ephedra ban, and FDA recently moved to dismiss the case...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099126

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel